Patrick began his career as a science and nanotechnology equity research analyst at Susquehanna International Group, authoring and marketing industry and equity research reports to hedge funds and portfolio managers. to develop a non-invasive method to detect blood glucose using Coherent Anti-Stokes Raman Spectroscopy (CARS) backed by Pfizer, Inc.
SynapDx went on to raise more than $40 million in venture capital to develop the first test to detect the early onset of autism using technologies licensed exclusively from Boston Children's Hospital and George Washington University. Prior to founding Portal Instruments, from 2009 to 2012, he was co-founder and director of strategic planning for SynapDx Corporation, where he had responsibility for development of the company's business and operational plans as well as securing Series A funding. Patrick brings more than 18 years of experience leading high-tech bioengineering companies from the lab to the market place and building world-class teams. Patrick Anquetil is the founder and CEO of Portal Instruments.
0 kommentar(er)
